Skip to main content
Premium Trial:

Request an Annual Quote

NIH Awards TriLink $750K Phase II Grant for Structure-Free DNA and RNA Research

NEW YORK, Dec. 15 (GenomeWeb News) - TriLink Bio Technologies has received an STTR Phase II funding from the National Institutes of Health to continue collaborating on the structure-free DNA and RNA program, the company said today.

 

Company spokesperson Kim Hampson told GenomeWeb News that the award is for $749,405 and will cover the period from January 2006 to Dec. 31, 2007.

 

TriLink is working with Howard Gamper of Thomas Jefferson University on the project, titled "Reagents for Preparing Structure-Free DNA and RNA." In Phase I, they demonstrated that certain base analogs can enhance accessibility of the pseudo-complementary target sequence to short probes.

 

The second phase of the project aims to improve the efficiency of hybridization between short oligonucleotide probes and long DNA and RNA targets, the company said.

 

In this collaboration, TriLink is developing the structure-free DNA and RNA technology while Gamper identifies the best nucleotide candidates which can be enzymatically incorporated into pseudo-complementary nucleic acid targets for improved hybridization performance.

 

The initial funding was for $99,871 from NIH and covered July to December.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.